| Literature DB >> 25977747 |
Konstantinos Voutetakis1, Aristotelis Chatziioannou1, Efstathios S Gonos1, Ioannis P Trougakos2.
Abstract
Several studies have employed DNA microarrays to identify gene expression signatures that mark human ageing; yet the features underlying this complicated phenomenon remain elusive. We thus conducted a bioinformatics meta-analysis on transcriptomics data from human cell- and biopsy-based microarrays experiments studying cellular senescence or in vivo tissue ageing, respectively. We report that coregulated genes in the postmitotic muscle and nervous tissues are classified into pathways involved in cancer, focal adhesion, actin cytoskeleton, MAPK signalling, and metabolism regulation. Genes that are differentially regulated during cellular senescence refer to pathways involved in neurodegeneration, focal adhesion, actin cytoskeleton, proteasome, cell cycle, DNA replication, and oxidative phosphorylation. Finally, we revealed genes and pathways (referring to cancer, Huntington's disease, MAPK signalling, focal adhesion, actin cytoskeleton, oxidative phosphorylation, and metabolic signalling) that are coregulated during cellular senescence and in vivo tissue ageing. The molecular commonalities between cellular senescence and tissue ageing are also highlighted by the fact that pathways that were overrepresented exclusively in the biopsy- or cell-based datasets are modules either of the same reference pathway (e.g., metabolism) or of closely interrelated pathways (e.g., thyroid cancer and melanoma). Our reported meta-analysis has revealed novel age-related genes, setting thus the basis for more detailed future functional studies.Entities:
Mesh:
Year: 2015 PMID: 25977747 PMCID: PMC4419258 DOI: 10.1155/2015/732914
Source DB: PubMed Journal: Oxid Med Cell Longev ISSN: 1942-0994 Impact factor: 6.543
Figure 1Identification of sex-specific age-related differentially expressed genes in human skeletal muscle. In skeletal muscle from aged males (M) (blue circle), 420 genes were found to be differentially expressed (P value ≤ 0.05; FDR ≤ 0.1; FC > 1.2), whereas 838 genes were differentially expressed in skeletal muscle from aged females (F) (pink circle). The intersection of the two groups refers to 46 genes; from these, 13 genes followed a sex-dependent expression pattern during ageing. The numbers of upregulated (↑) or downregulated (↓) DEGs along with the “hub-genes” linked to at least twenty Gene Ontology (GO) terms after pruning (revealed by the GORevenge algorithm) are indicated. The so-called “hub-genes” are linked to a plethora of Gene Ontology (GO) terms and are, likely, involved in numerous cellular procedures.
Age-regulated genes in human males' skeletal muscle.
| Function | Gene name | Gene description | Fold change | FDR |
|---|---|---|---|---|
| Glucose/lipid metabolism | H6PD | Hexose-6-phosphate dehydrogenase (glucose 1-dehydrogenase) | 2.35 | 0.013 |
| ALDOA | Aldolase A, fructose-bisphosphate | 0.12 | 0.062 | |
| ATP5S | ATP synthase, H+ transporting, mitochondrial Fo complex, subunit s (factor B) | 0.66 | 0.102 | |
| ZDHHC11 | Zinc finger, DHHC-type containing 11 | 2.04 | 0.032 | |
|
| ||||
| Signal transduction/G protein signalling | LEPR | Leptin receptor | 2.31 | 0.021 |
| LGR5 | Leucine-rich repeat-containing G protein-coupled receptor 5 | 2.34 | 0.126 | |
|
| ||||
| Stress response/redox homeostasis | ADH1B | Alcohol dehydrogenase 1B (class I), beta polypeptide | 2.17 | 0.044 |
| BPHL | Biphenyl hydrolase-like (serine hydrolase) | 0.59 | 0.027 | |
| GSTT1 | Glutathione S-transferase theta 1 | 0.63 | 0.108 | |
| GSR | glutathione reductase | 0.64 | 0.082 | |
| DHRS4L2 | Dehydrogenase/reductase (SDR family) member 4 like 2/dehydrogenase/reductase (SDR family) member 4 | 0.64 | 0.028 | |
| HSPA2 | Heat shock 70 kDa protein 2 | 1.91 | 0.092 | |
|
| ||||
| Cell adhesion/extracellular matrix organization | LUM | Lumican | 2.03 | 0.097 |
| MFAP5 | Microfibrillar associated protein 5 | 2.17 | 0.053 | |
| FN1 | fibronectin 1 | 1.91 | 0.085 | |
|
| ||||
| Unknown function | KIAA0240 | KIAA0240 | 2.10 | 0.015 |
| ABHD3 | Abhydrolase domain containing 3 | 2.34 | 0.034 | |
| KIAA1107 | Uncharacterized protein KIAA1107 | 0.56 | 0.069 | |
|
| ||||
| Synaptic function | LIN7C | lin-7 homolog C ( | 1.94 | 0.015 |
| LRP1B | Low density lipoprotein receptor-related protein 1B | 2.08 | 0.057 | |
| FCER1A | Fc fragment of IgE, high affinity I, receptor for; alpha polypeptide | 0.51 | 0.022 | |
| MTMR3 | Myotubular related protein 3 | 2.05 | 0.024 | |
| DDN | Dendrin | 2.05 | 0.04 | |
|
| ||||
| Cell growth/myelination | ID4 | Inhibitor of DNA binding 4, dominant negative helix-loop-helix protein | 2.04 | 0.051 |
| YPEL1 | Yippee-like 1 ( | 2.18 | 0.078 | |
| CRIM1 | Cysteine-rich transmembrane BMP regulator 1 (chordin-like) | 1.96 | 0.094 | |
| EMP1 | Epithelial membrane protein 1 | 2.02 | 0.039 | |
|
| ||||
| Inflammatory response | SOCS2 | Suppressor of cytokine signalling 2 | 0.49 | 0.041 |
| TACR1 | tachykinin receptor 1 | 0.61 | 0.024 | |
|
| ||||
| Mitochondrial/translation | MRPS16 | Mitochondrial ribosomal protein S16 | 0.51 | 0.036 |
| MRPL19 | Mitochondrial ribosomal protein L19 | 1.92 | 0.015 | |
|
| ||||
| Transcription | FRY | Furry homolog ( | 0.66 | 0.053 |
| ZFP36L2 | Zinc finger protein 36, C3H type-like 2 | 2.02 | 0.015 | |
| TET2 | tet oncogene family member 2 | 1.9 | 0.091 | |
|
| ||||
| Microtubule cytoskeleton | TUBB2A | Tubulin, beta 2A | 1.9 | 0.043 |
| TNNC1 | Troponin C type 1 (slow) | 0.15 | 0.082 | |
| TUBGCP4 | Tubulin, gamma complex associated protein 4 | 0.61 | 0.025 | |
| MAPT | Microtubule-associated protein tau | 0.57 | 0.061 | |
|
| ||||
| Muscle contraction | MYL1 | Myosin, light chain 1 | 0.64 | 0.094 |
|
| ||||
| Apoptosis | DAPK3 | Death-associated protein kinase 3 | 0.64 | 0.083 |
Shown genes are representative per functional group. Gene names by HUGO; fold changes [indicating differences in old versus young tissues (values <1 denote downregulation of the respective gene)] and statistical FDR values are indicated.
Age-regulated genes in human females' skeletal muscle.
| Function | Gene name | Gene description | Fold change | FDR |
|---|---|---|---|---|
| Lipid metabolism | GDE1 | Glycerophosphodiester phosphodiesterase 1 | 0.55 | 0.035 |
| FABP3 | Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor) | 0.55 | 0.019 | |
| ECHDC1 | Enoyl CoA hydratase domain containing 1 | 0.57 | 0.034 | |
| REPIN1 | Replication initiator 1 | 0.59 | 0.078 | |
|
| ||||
| Signal transduction/G protein signalling | NDRG2 | NDRG family member 2 | 0.42 | 0.041 |
| PDE11A | Phosphodiesterase 11A | 1.78 | 0.085 | |
| TNK2 | Tyrosine kinase, nonreceptor, 2 | 1.52 | 0.016 | |
| SMAD9 | SMAD family member 9 | 1.72 | 0.070 | |
| CNKSR2 | Connector enhancer of kinase suppressor of Ras 2 | 0.50 | 0.021 | |
| SH3BP5 | SH3-domain binding protein 5 (BTK-associated) | 2.12 | 0.022 | |
|
| ||||
| Stress response | HSPB6 | Heat shock protein, alpha-crystalline-related, B6 | 0.58 | 0.029 |
|
| ||||
| Cytoskeleton | SYNPO2 | Synaptopodin 2 | 1.88 | 0.045 |
| MYOM3 | Myomesin family, member 3 | 0.51 | 0.018 | |
|
| ||||
| Proteolysis | FBXO32 | F-box protein 32 | 1.63 | 0.064 |
| SPG7 | Spastic paraplegia 7 (pure and complicated autosomal recessive) | 0.52 | 0.031 | |
| DNAJC1 | DnaJ (Hsp40) homolog, subfamily C, member 1 | 1.51 | 0.050 | |
| TFRC | Transferrin receptor (p90, CD71) | 0.50 | 0.026 | |
|
| ||||
| Cell death/apoptosis | CABC1 | Chaperone, ABC1 activity of bc1 complex homolog (S. pombe) | 0.36 | 0.053 |
| YWHAE | Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, epsilon polypeptide | 0.58 | 0.038 | |
| SCOC | Short coiled-coil protein | 0.54 | 0.037 | |
|
| ||||
| Transmembrane transport | SLC16A3 | Solute carrier family 16, member 3 (monocarboxylic acid transporter 4) | 0.50 | 0.011 |
| TMED2 | Transmembrane emp24 domain trafficking protein 2 | 0.56 | 0.024 | |
|
| ||||
| Transcription | DNAJB6 | DnaJ (Hsp40) homolog, subfamily B, member 6 | 0.53 | 0.038 |
|
| ||||
| PHTF2 | Putative homeodomain transcription factor 2 | 0.54 | 0.045 | |
|
| ||||
| Mitochondrial/translation | MRPL4 | Mitochondrial ribosomal protein L4 | 0.56 | 0.038 |
Shown genes are representative per functional group. Gene names by HUGO; fold changes [indicating differences in old versus young tissues (values <1 denote downregulation of the respective gene)] and statistical FDR values are indicated.
Figure 2Identification of (gender-independent) coregulated potential biomarkers of ageing in human postmitotic skeletal muscle and nervous tissues. Venn diagram comparing DEGs in skeletal muscle and nervous tissues of young and aged individuals (P value ≤ 0.05; FDR ≤ 0.1; FC > 1.2). In skeletal muscle (light green; 6 experiments analysed), the total number of differentially expressed genes during ageing was 1551, while 387 genes were found to be differentially expressed during ageing of the nervous tissue (light yellow; 1 experiment analysed). The intersection of the two groups contains 66 common DEGs; the identified “hub-genes” (GORevenge algorithm) are listed in descending order of their GO terms' linkage number.
Figure 3Identification of (gender-independent) age-related KEGG pathways that are coregulated in human postmitotic skeletal muscle and nervous tissues. (a) Venn diagram comparing differentially regulated KEGG pathways during ageing of human skeletal muscle and nervous tissues; data were assessed by the StRAnGER algorithm. The green circle represents the number of KEGG pathways as derived by the combinatorial analysis of six different experiments in skeletal muscle, whereas the blue circle represents the identified KEGG pathways as derived by the analysis of the GDS707 nervous tissue related dataset. The overlapping grey area represents those KEGG pathways that are commonly affected by ageing in the two tissues. (b) Distribution of the common overrepresented KEGG pathways in tissue datasets based on their (%) enrichment score. The (%) enrichment score represents the (%) ratio of the number of appearances of a KEGG ontology term in the list of DEGs versus the number which indicates the times that this KEGG ontology term exists in the annotation file of each microarray platform.
Figure 4Venn diagram highlighting unique or shared DEGs during cellular senescence of the four human cell lines assayed. The numbers of differentially expressed genes (P value ≤ 0.05; FDR ≤ 0.1; F.C > 1.2) in HDFs (red frame); HSCs (blue frame); T-cells (green frame); and HMECs (purple frame) during cellular senescence are indicated. The two shaded intersections represent commonly regulated DEGs (respective genes are listed in each case) during cellular senescence of HDFs-HSCs-HMECs and of HDFs-HSCs-T-cells, respectively.
Figure 5Differentially regulated human genes during cellular senescence and in vivo tissue ageing. (a) Venn diagram showing the differentially regulated genes (P value ≤ 0.05; FC ≥ 1.5) during cellular senescence and in vivo tissue ageing. The yellow circle represents the number of DEGs derived by the merging of five different datasets (experiments) of the cell-based transcriptomics data, while the blue circle represents the number of DEGs derived by the merging of seven different datasets (experiments) of in vivo tissue ageing transcriptomics. The overlapping “green” area indicates the number of DEGs that are common in both conditions. (b) Two-way hierarchical clustering analysis based on the expression profiles of the common differentially expressed genes. Each column represents the gene expression levels per dataset and each row denotes the corresponding gene. Red and dark-green colours indicate that the obtained values are greater than 1.5-fold or less than −1.5-fold, respectively; grey colour indicates statistically not significant changes or not expressed genes. Gene symbols are given in the left. HSCs-1: PBCD34+38−. HSCs-2: BMCD34+.
Figure 6Significantly enriched KEGG pathways, which are deregulated during human ageing. (a) Venn diagram of KEGG pathways identified as overrepresented among the transcripts significantly up- or downregulated (P value ≤ 0.05; FDR ≤ 0.1) in cell- and biopsy-based transcriptomics; only KEGG pathways with count-threshold ≥2 (minimum number of genes for each KEGG pathway) were considered. The green circle represents the total number of KEGG pathways as derived by the combination of five different experiments, whereas the blue circle represents the number of KEGG pathways as derived by the analysis of seven different experiments; the overlapping area represents the common KEGG pathways (indicated in bold in Figure 6(b)). (b) Heatmap of the enrichment (%) score of predicted KEGG pathways in the context of the five cell- and seven biopsy-based datasets. Columns represent the enrichment score (%) of KEGG pathways per dataset and rows indicate the individual KEGG pathway; empty cells denote statistically not significant or no overrepresented KEGG pathway. M: male; F: female; skeletal muscle 1 (M): GDS287; skeletal muscle 2 (M): GDS156; skeletal muscle 3 (M): GDS288; skeletal muscle 4 (F): GDS472; skeletal muscle 5 (F): GDS473; skeletal muscle 6 (M, F): GSE5086; HSCs-1: PBCD34+38− cells; HSCs-2: BMCD34+ cells.